DANIEL ERNESTO CASTELLANO GAUNA-rekin lankidetzan egindako argitalpenak (7)

2021

  1. Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.

    OncoImmunology, Vol. 10, Núm. 1

  2. Systemic Analysis and Review of Nivolumab-ipilimumab Combination as a Rescue Strategy for Renal Cell Carcinoma After Treatment With Anti–PD-1/PD-L1 Therapy

    Clinical Genitourinary Cancer, Vol. 19, Núm. 2, pp. 95-102

2020

  1. Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials

    Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 2126-2129

  2. Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy

    Cancers, Vol. 12, Núm. 7, pp. 1-13

  3. The value of pd-l1 expression as predictive biomarker in metastatic renal cell carcinoma patients: A meta-analysis of randomized clinical trials

    Cancers, Vol. 12, Núm. 7, pp. 1-16

2019

  1. Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: A meta-analysis of randomized clinical trials

    Oncotarget, Vol. 10, Núm. 35, pp. 3294-3301

2018

  1. Analysis of response rate with ANTI-PD1/PDL-1 monoclonal antibodies in advanced solid tumors: A meta-analysis of randomized clinical trials

    Oncotarget, Vol. 9, Núm. 9, pp. 8706-8715